Industrial Policy & Trade Monitor· 2666 actions· ✨ 90 recent

On 1 May 2026 the trade pillar of the EU-Mercosur Partnership Agreement (the "Interim Trade Agreement", iTA) entered provisional application between the European Union and the four Mercosur states — Argentina, Brazil, Paraguay and Uruguay — following its publication in the EU Official Journal on 27 February 2026 alongside the broader EU-Mercosur Partnership Agreement (EMPA). The iTA covers goods (eliminating duties on more than 90% of bilateral trade over a transition period including immediate cuts on cars, pharmaceuticals, wine and olive oil), services, government procurement at federal and state level, intellectual property (344 EU geographical indications protected), SPS/TBT disciplines, and a sustainability chapter. Mercosur receives tariff-rate quotas on agri-food exports (beef, poultry, sugar, ethanol, honey). Provisional application proceeds pending full ratification of EMPA by the Council, European Parliament and all EU national parliaments and a pending CJEU opinion; only the trade pillar applies provisionally.

On 27 January 2026 the European Union and India announced the conclusion of negotiations on a comprehensive Free Trade Agreement at the EU-India summit hosted at Hyderabad House in New Delhi, attended by PM Narendra Modi, Commission President Ursula von der Leyen and Council President António Costa. The deal — described by both leaders as the "mother of all deals" — covers ~25% of world GDP and ~2 billion people. The EU eliminates duties on 91% of tariff lines (covering 99.3% of bilateral trade by value); India eliminates duties on 86% of lines (covering 96.6% by value). Headline cuts include Indian tariffs on EU wines (150% → 75% at entry into force, falling to 20%), olive oil (45% → 0% over five years) and processed agri-food (up to 50% eliminated); EU tariffs are reduced/eliminated on Indian textiles, leather/footwear, gems and jewelry, marine products, tea, coffee, spices and certain agricultural and steel products. The agreement still requires Council adoption, European Parliament consent and approval by India's Union Council of Ministers; entry into force is expected in early 2027. Companion instruments concluded at the same summit include an EU-India Security and Defence Partnership and a Mobility and Migration Agreement.

China's Ministry of Finance issued Caiku [2025] No. 19 on 3 July 2025, effective 6 July 2025, restricting EU-origin medical devices in Chinese government procurement. For procurement projects with budgets of CNY 45 million (~USD 6.3 million) or more, purchasers must exclude EU enterprises (excluding EU-invested enterprises operating in China) from participation where imported products are genuinely required; non-EU bidders that do participate may not source more than 50% of the contract value from EU-imported medical devices. Contracts already awarded before the effective date are grandfathered. The notice is explicitly framed as a reciprocal response to the European Commission's 20 June 2025 measure restricting Chinese medical-device firms and products from EU public procurement under the EU's International Procurement Instrument (IPI).

The European Commission adopted Commission Implementing Regulation (EU) 2025/1197 on 19 June 2025, published in the Official Journal on 20 June 2025 and applicable from 30 June 2025. It imposes the EU's first-ever International Procurement Instrument (IPI) measure, excluding tenders submitted by economic operators originating in China from EU public procurement contracts for medical devices (CPV codes 33100000-1 to 33199000-1) valued at EUR 5,000,000 or more net of VAT. Even where a non-Chinese bidder wins, no more than 50% of the contract's value may be sourced from China-origin medical devices (IPI Article 8(1)). Contracting authorities may waive the measure only where solely Chinese bidders meet requirements or for overriding public-interest reasons (IPI Article 9(1)).